In the latest session, Vir Biotechnology Inc (NASDAQ: VIR) closed at $9.49 up 1.61% from its previous closing price of $9.34. On the day, 649655 shares were traded.
Ratios:
For a deeper understanding of Vir Biotechnology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.05 and its Current Ratio is at 9.05. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 03 ’24 when De Backer Marianne sold 72,995 shares for $9.46 per share. The transaction valued at 690,365 led to the insider holds 678,457 shares of the business.
HANLY ANN M. sold 2,711 shares of VIR for $27,251 on Apr 01 ’24. The EVP & Chief Technology Officer now owns 132,069 shares after completing the transaction at $10.05 per share. On Mar 27 ’24, another insider, Lee Sung, who serves as the EVP & Chief Financial Officer of the company, sold 6,008 shares for $9.89 each. As a result, the insider received 59,404 and left with 100,492 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 1.28B and an Enterprise Value of -116.41M. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.87 while its Price-to-Book (P/B) ratio in mrq is 0.80. Its current Enterprise Value per Revenue stands at -2.95 whereas that against EBITDA is 0.18.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $27.48, while it has fallen to a 52-week low of $7.72. The 50-Day Moving Average of the stock is 10.17, while the 200-Day Moving Average is calculated to be 11.63.
Shares Statistics:
For the past three months, VIR has traded an average of 1.10M shares per day and 776.62k over the past ten days. A total of 134.78M shares are outstanding, with a floating share count of 88.08M. Insiders hold about 34.77% of the company’s shares, while institutions hold 53.44% stake in the company. Shares short for VIR as of Mar 15, 2024 were 5.43M with a Short Ratio of 4.94, compared to 5.05M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.02% and a Short% of Float of 6.76%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.05 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.32, while EPS last year was -$1.06. The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.91 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$3.43 and -$4.94 for the fiscal current year, implying an average EPS of -$4.09. EPS for the following year is -$3.98, with 9 analysts recommending between -$2.83 and -$5.66.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $11.99M this quarter.It ranges from a high estimate of $39.4M to a low estimate of $4.26M. As of the current estimate, Vir Biotechnology Inc’s year-ago sales were $50.1M, an estimated decrease of -76.10% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $9.35M, an increase of 146.20% over than the figure of -$76.10% in the same quarter last year. There is a high estimate of $21.3M for the next quarter, whereas the lowest estimate is $6M.
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $121.8M, while the lowest revenue estimate was $22.69M, resulting in an average revenue estimate of $41.37M. In the same quarter a year ago, actual revenue was $86.18M, down -52.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $41.61M in the next fiscal year. The high estimate is $106.2M and the low estimate is $17.69M. The average revenue growth estimate for next year is up 0.60% from the average revenue estimate for this year.
